NSW Opens RNA Manufacturing Hub for Vaccines and Cancer Therapies
The $96 million facility will produce mRNA and synthetic RNA, as the U.S. government moves to reduce funding for mRNA vaccine development.
Syringes and vials of the Pfizer-BioNTech COVID-19 vaccine are prepared to be administered to healthcare workers at a drive-up vaccination site in Reno, Nev., on Dec. 17, 2020. Patrick T. Fallon/AFP via Getty Images
New South Wales (NSW) has opened a $96 million RNA research and pilot manufacturing facility at Macquarie University, a move aimed at strengthening Australia’s ability to develop vaccines and advanced therapies locally.
The new hub will produce messenger RNA (mRNA), synthetic RNA, lipid nanoparticles, and plasmid DNA on a small scale.
Monica O’Shea
Author
Monica O’Shea is a reporter based in Australia. She previously worked as a reporter for Motley Fool Australia, Daily Mail Australia, and Fairfax Regional Media. She can be reached at monica.o'[email protected]
